Extended collaboration will further explore the capabilities of Medidata Platform from early-phase trials to post-marketing ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights increased data management, DE&I, and ...

Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...

Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...

In the Phase I dose escalation portion, which evaluated the combination in participants with small cell lung cancer, the first patient treated attained partial remission.

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, looks back to 2024 and discusses some of the industry’s ...

End-to-end offering is designed to streamline site activation and optimize visibility in critical research processes.

Use of decentralized approach in a Phase 1 pharmacokinetic trial shows the ability to enable remote data collection and ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights how artificial intelligence, real-time monitoring, and historical data can aid in optimizing trial design.

Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...